XML 17 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments (Details 2) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance $ 13,960
Assumed payments made by Pfizer or assignee (3,310)
Fair value adjustments recorded as unrealized gain on available-for-sale securities 2,914
Fair value adjustments to co-promote termination liability 2,522
Transfer of available-for-sale investments from level 3 to level 1 (4,340)
Ending Balance 11,746
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance 23,647
Assumed payments made by Pfizer or assignee (3,310)
Fair value adjustments for amounts owed related to restricted investments and recorded as other expense 437
Payments to CVR and other former license holders (989)
Fair value adjustments to contingent liabilities (599)
Fair value adjustments to co-promote termination liability 2,522
Transfer of liability for restricted investments owed to former licensees from level 3 to level 1 (651)
Ending Balance $ 21,057